One stock in this five-name healthcare basket costs more in annual tax than the other four combined, and the IRS treats its payout differently from the rest. Find out which one belongs in your Roth first.
AbbVie generates significant cash flow from its newer immunology stars, Skyrizi and Rinvoq. Eli Lilly is seeing explosive revenue growth driven by its dominant presence in the metabolic health market.
NORTH CHICAGO, Ill., Nov. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026.
Advisors Asset Management Inc. acquired a new stake in AbbVie Inc. (NYSE: ABBV) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 133,738 shares of the company's stock, valued at approximately $34,985,000. A number of other hedge funds and other institutional investors also
Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.
Bridges Investment Management Inc. cut its position in shares of AbbVie Inc. (NYSE: ABBV) by 6.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 181,902 shares of the company's stock after selling 11,541 shares during the period. Bridges Investment
ABBV's neuroscience franchise delivers 19.5% operational sales growth in Q3, prompting the company to raise its 2026 segment sales outlook to $13 billion.
Selling shares in a down market can turn a retirement plan into a slow leak. Five dividend payers across five sectors aim to cover the bills instead, but one of them carries $166.2B of debt, and each one hides a risk worth knowing first.
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.